Kornimate/medical-research-clean huggingface dataset:
resistance of helicobacter pylori to antibiotics in children

Conditions: Abdominal Pain; Children; Bacterial Infection Due to Helicobacter Pylori (H. Pylori); Antibiotic Resistant Strain

Summary: helicobacter pylori (hp) is one of the most common pathogens in humans. this infection can present in children with abdominal pain, vomiting and iron deficiency. the treatment is usually empiric and includes antibiotic treatment usually amoxycillin and clarithromycin or metronidazole. between 40 to 70 % of the pathogens are resistant to those drugs, and it is important to characterize the specific sensitivity of the pathogens in any specific area and in pediatric population. the aims of this study is to assess the sensitivity of hp in pediatric population in northern israel.

the aim of our prospective study is to investigate the rate of h pylori resistant strains to antibiotic treatment including amoxicillin, clarithromycin, metronidazole, tetracycline and quinolones in pediatric population in ha-emek medical center, afula. the second aim was to determine if in vitro resistance is being reflected in vivo too. should the investigators find high rates of h pylori resistance to clarithromycin, the investigators will have to reconsider the recommendation to use clarithromycin as the first line treatment for h pylori. our research group will conclude 100 children in the ages of 1-18 years, evaluated for recurrent abdominal pain, iron deficiency anemia, failure to thrive by an upper endoscopy, biopsy specimens taken for a rapid urease test, for histology, for culture and for antibiotic susceptibility testing. biopsy specimens for histology will be fixed in formalin, embedded in paraffin and sectioned and stained with hematoxylin and eosin. the microbiological workup will include an imprint of the biopsy on a slide followed by a gram stain for the purpose of demonstrating h. pylori in situ. further the biopsies will be streaked out on chocolate agar, sheep blood agar and h. pylori selective agar supplemented with polymixin to suppress possible contaminants. 4 days of incubation in a micro aerophilic atmosphere will follow . susceptibility testing of h pylori will be performed with e test on mueller hinton agar supplemented with defibrinated sheep blood using a macfalrland 3.0 density of a bacterial suspension. reading the susceptibility will take place following 72 hours of incubation in a micro aerophilic atmosphere.

Eligibility criteria:
inclusion criteria: * ages of 1-18 years, * evaluated for recurrent abdominal pain, * iron deficiency anemia, * failure to thrive by an upper endoscopy
phase ii trial to assess the radiosensitizing effect of zarnestra in patients with glioblastoma multiforme

Conditions: Glioblastoma Multiforme

Summary: the purpose of this study is to determine the efficacy by the determination of the time to progression (ttp) in patients with resectable gbm or non surgical gbm with a size less than 5 cm treated with the combination of zarnestra plus radiation therapy.


Eligibility criteria:
inclusion criteria: * patients must have pathologically confirmed (histology or cytology), resectable or non resectable, glioblastoma multiforme with a size \< 5 cm on mri if non resectable * patients must be at least 7 days but no more than 2 months since surgery or biopsy. * patients must have an ecog performance status ≤ 2. * patients must be aged 18 * patient has signed the informed consent form exclusion criteria: * patients with unresectable glioblastoma with a size \>5 cm on mri * patients with clinically apparent leptomeningeal metastases * patients with uncontrolled seizures despite standard anticonvulsant therapy * any prior systemic treatment (chemotherapy, immunotherapy, hormonal therapy) for glioblastoma multiforme * significantly abnormal haematological status as judged by: absolute neutrophil count (anc) \< 1500/mm3 (1.5\*109/l) platelet count \<100,000/mm3 (100\*109/l) * serum bilirubin \>2 mg/dl (\>34 mmol/l) or transaminase \>2.5x the upper limit of institutional normal or creatinine \>1.5 mg/dl (\>132 mmol/l) * inability to co-operate with the treatment protocol * patients who cannot undergo imaging evaluations * participation in an investigational drug trial in the 30 days prior to selection * pregnant or nursing mothers. (female patients of childbearing potential must use adequate contraception.) * any malignancy within the past five years. exceptions are: superficial basal cell carcinoma or non-metastatic squamous cell cancer of the skin, cervix cancer (cervical intra-epithelial neoplasia -cin or figo stage 1) or prostate intra-epithelial neoplasia (pin), biochemical relapse free for at least 3 years. * any prior systemic chemotherapy in the past five years for any malignancy in the medical history * any concurrent disease that in the opinion of the investigator would constitute a hazard for participating in this study * known sensitivity to imidazole derivatives * patients under law protection * medical history of phlebitis or pulmonary embolism, thrombocytosis, myocardiopathy, or other relevant cardiac pathology (auricular flutter, auricular fibrillation) * medical history of immuno-allergic pneumopathy

Keywords: glioblastoma multiforme zarnestra radiation therapy
effect of lumacaftor/ivacaftor in children with cystic fibrosis homozygote for f508del on small airway function

Conditions: Cystic Fibrosis in Children

Summary: to obtain prospective real world data of the effect of lumacaftor/ivacaftor or tezacaftor/ ivacaftor on small airway disease in children aged 6-18 years with cystic fibrosis (cf) homozygous for f508del. the effect of the medication on small airway disease is evaluated by measurement of multiple breath washout (mbw) with its outcome parameter lung clearance index (lci) and the perth-rotterdam annotated grid morphometric analysis for cf (pragma-cf) cpmputed tomography (ct) score. in addition the relation between changes in lci and pragma-cf score is evaluated.

multi-center observational study. duration 12 months after the start of lumacaftor/ ivacaftor or tezacaftor/ ivacaftor . to collect these data and to assist in clinical decisions regarding initiation and continuation of lumacaftor/ivacaftor or tezacaftor/ ivacaftor, the investigators of the cf center (beatrix children's hospital, university medical center groningen (umcg), the netherlands) developed an extensive protocol of testing before children aged 6-18 years start therapy and during the first year after start. the protocol includes the following tests: growth parameters, sweat test, lung function testing (spirometry, mbw, body plethysmography), blood test panel (ast, alt, alkalic phosphatase (af), total and direct bilirubin, ldh), fecal elastase, high resolution (hr)ct and cf quality of life questionnaires. these tests are repeated at regular intervals. multi-center observational study. duration 12 months after the start of lumacaftor/ ivacaftor or tezacaftor/ ivacaftor .

Eligibility criteria:
inclusion criteria: * children aged 6-18 years * cf, homozygote f508del confirmed by dna analysis * considered for start of lumacaftor/ ivacaftor or tezacaftor/ivacaftor exclusion criteria: * - unable to perform acceptable, repeatable lung function tests

Keywords: lumacaftor/ ivacaftor tezacaftor/ ivacaftor multiple breath washout lung clearance index pragma cf score
investigation of intravenous (iv) administration of an approved drug (mk-0476, montelukast sodium) for acute asthma (mk-0476-288)

Conditions: Asthma

Summary: the purpose of this study is to evaluate improved results of treatment for patients entering an emergency department with asthma attacks when given an investigational iv administration of an approved drug (mk-0476, montelukast sodium) in addition to approved standard treatment.


Eligibility criteria:
inclusion criteria: * individuals with acute asthma exclusion criteria: * women of child bearing age * history of chronic obstructive pulmonary disease (copd)
the effect of radioactive iodine administration for thyroid diseases on h.pylori eradication

Conditions: Helicobacter Pylori Infected Patients; Thyroid Cancer Patients; Hyperthyroidism

Summary: because of the high iodine uptake in the stomach, radioactive iodine treatment for thyroid diseases (cancer or hyperthyroidism) or radioactive iodine administered for thyroid scan may be able to eradicate h.pylori infection from the stomach of patients infected with h.pylori. also to test the hypothesis that caga virulent strains of h.pylori are more common in patients with thyroid cancer than with other thyroid diseases.

objective to test eradicate h.pylori after administration of radioactive iodine (131i) to patients with thyroid diseases and to evaluate their h.pylori caga status . design observational study setting the isotopic institute at the rabin medical center, campus beilinson patients consecutive patients with thyroid diseases referred to the isotopic institute at the rabin medical center, campus beilinson for either radioactive iodine (131i) thyroid scan or radioactive iodine (131i)treatment for their disease, will be screened, prior to the radioactive iodine, for h. pylori infection and caga protein by serology. patient with positive serology for h. pylori will be tested for active gastric infection using the h.pylori stool antigen test. the study population will include all patients who tested positive for h.pylori both by serology and stool antigen tests. six to eight weeks and 6 month after administration of radioactive iodine (131i) treatment , stool antigen or h.pylori will be tested again to confirm persistence of h.pylori eradication. main outcome measure confirmed h.pylori eradication by the stool antigen test. the rate of infection with virulent and caricogenic caga h.pylori ,will be tested using the immunoblot assay. summary we will test in this study whether helicobacter pylori is eradicated, after radioactive iodine (131i) administration, from the stomach of patients with thyroid diseases. the rate of caga virulent and carcinogenic h.pylori infection in theses patients will be assessed.

Eligibility criteria:
inclusion criteria: * adult patients between the ages of 18 and 80. * patients with diagnosed thyroid disease referred for thyroid scan or treatment with radioactive iodine (131i). * patients who provide informed consent exclusion criteria: * patients without diagnosed thyroid disease. * patients who are pregnant or breast feeding. * patients who have received previous treatment for h. pylori infection. * patients taking proton pump inhibitors. * patients with recent or current use of antibiotics. * patients allergic to iodine (131i).

Keywords: radioactive iodine helicobacter pylori thyroid diseases caga
using lignocaine spray and gel to reduce the pain associated with nasogastric tube insertion in children

Conditions: Intubation; Difficult

Summary: nasogastric tube insertion is one of the most common invasive procedures performed in children's hospitals, and has long been recognised as one of the most traumatic and painful. as a once off procedure, a nasogastric tube insertion is extremely distressing but the repeated procedures that many children endure as a necessary part of treatment for a chronic disease can be so traumatic that psychological damage may occur. there have been a limited number of studies carried out which have looked at methods to reduce the pain and trauma associated with this procedure, but most of these have been carried out in the adult population. the investigators propose to carry out a research project in a paediatric setting to definitively investigate the use of local anaesthetic spray, in combination with local anaesthetic gel, to numb the nasal passages and the back of the throat, with the aim of reducing or removing the unpleasant sensation of the nasogastric tube placement. if the study shows a benefit from the use of local anaesthetics, it would be an inexpensive and easily incorporated intervention that could be inserted into the routine procedure for nasogastric tube insertion.


Eligibility criteria:
inclusion criteria: 1. signed informed consent from parent of guardian 2. signed assent from subject 3. subject must have insertion of a nasogastric tube ordered as part of his/her current treatment 4. must be 6 years of age or older 5. must be able to complete visual analogue scale (vas) exclusion criteria: 1. congenital abnormalities of the naso/oropharyngeal area 2. any surgical alterations in the naso/oropharyngeal area 3. mucositis 4. known history of hypersensitivity to xylocaine or other local anaesthetics 5. known history of hypersensitivity to other components of the xylocaine solutions such as methyl or propyl hydroxybenzoate, ethanol, polyethylene glycol 400, banana flavour phl-131980, menthol, saccharin 6. allergy to food colouring 7. presence of tracheotomy / tracheostomy 8. presence of tumour in the nasopharyngeal/oropharyngeal area 9. impaired gag reflex 10. impaired swallow 11. any cardiac condition 12. diabetes 13. hypertension 14. current use of antidepressant medication 15. current use of cimetidine or propranolol 16. significantly impaired liver function 17. significantly impaired renal function 18. current use of anti-arrhythmic medication

Keywords: pain discomfort insertion nasogastric tube
outcomes of intraoperative 5-fluorouracil versus mitomycin c

Conditions: Glaucoma

Summary: a clinical trial to establish the long term response of using intraoperative 5-fluorouracil (5-fu) versus mitomycin c (mmc) in trabeculectomy glaucoma surgery. antiproliferative agents such as 5-fluorouracil and mitomycin c have been used extensively in trabeculectomy surgery to improve the success of the surgery and prevent further visual loss and blindness in glaucoma patients.

glaucoma is a life-long progressive disease, and patients are living longer. therefore, a long term full evaluation of the efficacy of intraoperative 5-fu and mmc needs to be performed to assess the true efficacy of mmc compared to 5-fu. we, therefore propose, a long-term prospective study of patients previously enrolled in the prospective study involving the evaluation of single intraoperative application of mitomycin c versus 5-fluorouracil in low to moderate risk glaucoma patients.

Eligibility criteria:
inclusion criteria: * only patients deemed successful as 36 months will be included. these patients will have participated in the randomized prospective study trial comparing intraoperative 5-fu and mitomycin c in primary trabeculectomy. exclusion criteria: * only patients deemed successful as 36 months will be included. these patients will have participated in the randomized prospective study trial comparing intraoperative 5-fu and mitomycin c in primary trabeculectomy.

Keywords: trabeculectomy 5-fluorouracil mitomycin c
oropharyngeal dysphagia in patients with community acquired pneumonia

Conditions: Dysphagia; Pneumonia

Summary: this study investigates relationship between community acquired pneumonia and oropharyngeal dysphagia in patients admitted to a department of respiratory medicine in northern denmark. the endpoints will be re-hospitalisation and mortality.

community acquired pneumonia (cap) is an important cause of morbidity and mortality in elderly patients. risk factors are many including oropharyngeal dysphagia (od). systematic screening of od is recommended for at-risk popolations, however these resommandations do not specifically address elderly patients hospitalized with cap. in this study od is assessed in all patients by volume-viscosity swallowing test (v-vst) the study is registered by the danish data protection authority (2008-58-0028)

Eligibility criteria:
inclusion criteria: * temperature \> 38 degrees celcius * new infiltrate on chest x-ray * increased c-reactive protein (crp) * either cough, dyspnea, pleuritic chest pain, expectoration, or tachypnea exclusion criteria: * patients referred from the intensive care unit * reduced cognitive awareness if not able to able to cooperate with the assessment of oropharyngeal dysphagia

Keywords: dysphagia community acquired pneumonia mortality rehospitalization
risk of syncopal relapses in patients treated with permanent pacing for bradyarrhythmic syncope

Conditions: Syncope

Summary: prospective, multicenter, observational registry designed to collect data on syncopal relapses in patients undergoing pacemaker implantation for bradyarrhythmic syncope.

prospective, multicenter, observational registry designed to collect data on syncopal relapses in patients undergoing pacemaker implantation for bradyarrhythmic syncope. all consecutive patients aged ≥18 years who underwent pacemaker implantation for syncope of bradyarrhythmic aetiology (proven or presumed) at participating centers from january 2010 to december 2013 were enrolled in the registry. during follow-up the occurrence of the first syncopal relapse after pacemaker implantation is recorded.

Eligibility criteria:
inclusion criteria: * patients undergoing pacemaker implantation for bradyarrhythmic syncope exclusion criteria: * age \<18 years

Keywords: syncope, pacemaker, bradyarrhythmias
immunotherapy of advanced cancer using a combination nimotuzumab and nk cells

Conditions: Advanced Cancer; ADCC; NK Cell Mediated Immunity; Nimotuzumab; Adaptive Transfer

Summary: nk cells can persist and expand in vivo following adoptive transfer and may have a role in the treatment of late stage malignancies. nk also express an activating fc receptor that mediates antibody-dependent cellular cytotoxicity (adcc) and production of immune modulatory cytokines in response to antibody-coated targets. nimotuzumab, an monoclonal antibody against egfr (epidermal growth factor receptor), may enhance the adcc effect of nk cell. this study will evaluate the safety of combination of nimotuzumab and nk cell in treating advanced cancer patients. blood samples will also be collected for research purposes.

this is a phase i clinical study of expanded nk cells from autologous origin. the nk cell will be selected and expanded ex vivo and infused back into patients. nimotuzumab will be used 24 hours before infusion. 21 advanced cancer patients are planned to receive two cycles of nk cells and nimotuzumab treatment. biomarkers and immunological markers are collected and analyzed as well.

Eligibility criteria:
inclusion criteria: 1. histologically confirmed recurrent or metastatic cancer 2. measurable disease 3. progressed after all standard treatment 4. ecog performance status of 0 to 2 5. expected life span ≥ 3 months 6. toxicities from prior treatment has resolved. washout period is 4 weeks for chemotherapy, and 2 weeks for targeted therapy 7. major organs function normally 8. women at pregnant ages should be under contraception 9. willing and able to provide informed consent exclusion criteria: 1. other malignancy within 5 years prior to entry into the study, expect for treated non melanoma skin cancer and cervical carcinoma in situ 2. poor vasculature 3. disease to the central nervous system 4. blood-borne infectious disease, eg. hepatitis b 5. history of mandatory custody because of psychosis or other psychological disease inappropriate for treatment deemed by treating physician 6. with other immune diseases, or chronic use of immunosuppressants or steroids 7. pregnancy (women of childbearing potential: refusal or inability to use effective means of contraception) 8. breastfeeding 9. decision of unsuitableness by principal investigator or physician-in-charge
efficacy and safety of oral sumatriptan plus oral promethazine in migraine treatment

Conditions: Migraine With Aura; Migraine Without Aura

Summary: the purpose of this study is to show the efficacy of promethazine in management of patients with moderate to severe migraine


Eligibility criteria:
inclusion criteria: * patients who aged 18 to 65 years with a clinical history of migraine with or without aura (international headache society categories 1.1 or 1.2) for at least 1 year * subjects who have mean frequency of 2-8 migraine attacks per month. exclusion criteria: * complex form of migraine, medication overuse headache, history of chronic tension-type headache, ophthalmoplegic, basilar and hemiplegic migraine * uncontrolled hypertension (diastolic blood pressure \>95 mm hg or systolic blood pressure \>160 mm hg) * history or clinical evidence of cerebrovascular or cardiovascular disorder * renal impairment or dialysis dependence * serious illness (physical or psychiatric disorders) * drugs and alcohol abuse * pregnancy and breastfeeding * allergy or hypersensitivity to promethazine or triptans * concurrent use of ergotamine-containing drugs, monoamine oxidize inhibitors, antidepressant, lithium
treatment patterns and clinical outcomes among patients with advanced renal cell carcinoma (arcc) receiving systemic first-line (1st line) anti-cancer treatment under daily routine in germany: retrospective medical chart review (renalistic study).

Conditions: Carcinoma, Renal Cell

Summary: the purpose of this study is to learn about the treatments used in for advanced renal cell carcinoma as well as effectiveness of these treatments in the real world. study participants must be: at least 18 years of age or older. confirmed renal cell carcinoma received first line treatment


Eligibility criteria:
inclusion criteria: * participants diagnosed with locally advanced or metastatic renal cell carcinoma * participants with full medical information is available regarding all treatments before, during and after 1st line exclusion criteria:

Keywords: real world chart review retrospective germany